BibTex RIS Kaynak Göster

Study on thiazolyl-hydrazone derivatives as acetylcholinesterase inhibitors

Yıl 2014, Cilt: 4 Sayı: 1, 38 - 42, 25.04.2014

Öz

Objective: In this study we aimed to synthesize some hydrazone derivatives of thiazole and to evaluate their anticholinesterase activities. 

Method: Pyrrole-2-carboxaldehydes were reacted directly with thiosemicarbazide in ethanol and then obtained thiosemicarbazones were condensed with ?-bromoacetophenone derivatives (Hantzsch reaction) to give 1-substituted pyrrole-2-carboxaldehyde (4-(4-substituted phenyl)-1,3-thiazol-2-yl) hydrazones. The structures of the obtained compounds were elucidated by using IR, 1H-NMR and FAB+-MS spectral data and elemental analyses results. In the pharmacological studies, anticholinesterase activities of these compounds have been evaluated by using modified Ellman’s spectrophotometric method.

Results: The compound (1) can be identified as the most active anticholinesterase molecule due to its inhibitory effect on acetylcholinesterase with inhibition percentages of 64.10 (1 mM) and 33.00 (0.1 mM) % and also IC50 value of 0.59 mM. 

Conclusion: The substitutions on phenyl ring at para position and at first position of pyrrole ring have negatively affected anticholinesterase activity.

Key words: Thiazole, hydrazone, pyrrole, anticholinesterase activity

Kaynakça

  • Aderinwale GO, Ernst HW, Mousa SA. Current therapies and new strategies for the management of Alzheimer’s Disease. Am J Alzheimers Dis Other Demen. 2012;25: 414-424.
  • Dipiro J, Talbert RL, Yee GC, Matzke GR, Wells BG. Alzheimer’s disease. In: Jennifer Dea, eds. Pharmacotherapy: A Pathophysiology Approach. New York: NY McGraw-Hill; 2005.
  • Salloway S, Correia S. Alzheimer disease: time to improve its diagnosis and treatment. Cleve Clin J Med. 2009;76(1): 49-58.
  • Terry Jr. AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306: 821-827.
  • Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001; 81: 741-766.
  • Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res. 2004; 5: 433-440.
  • Asadipour A, Alipour M, Jafari M, Khoobi M, Emami S, Nadri H, Sakhteman A, Moradi A, Sheibani V, Moghadam FH, Shafiee A, Foroumadi A. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem. 2013; 70: 623-630.
  • Siddiqui N, Arshad MF, Ahsan W, Alam MS. Thiazoles: a valuable insight into the recent advances and biological activities. Int J Pharm Sci Drug Res. 2009; 1: 136-143.
  • Mustafa SM, Naira VA, Chittoorb JP, Krishnapillaic S. Synthesis of 1,2,4-triazoles and thiazoles from thiosemicarbazide and its derivatives. Mini-Rev Org Chem. 2004;1: 375-385.
  • Andreani A, Burnelli S, Granaiola M, Guardigli M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Rizzoli M, Varoli L, Roda A. Chemiluminescent high-throughput microassay applied to imidazo [2,1-b]thiazole derivatives as potential acetylcholinesterase and butyrylcholinesterase inhibitors. Eur J Med Chem. 2008;43: 657-661. Sengupta AK, Garg M. New 5-arylamino-2[N-(2’mercaptoacetylamino-4’-arylthiazolo)]thiadiazoles(III): as AChE inhibitors. J Indian Chem Soc. 1980;57: 1241-1243.
  • Shaw FH, Bentley GA. The pharmacology of some new anticholinesterases. Aust J Exp Biol Med Sci. 1953;31: 573–576.
  • Matsunaga Y, Tanaka T, Yoshinaga K, Ueki S, Hori Y, Eta R. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336: 791-800.

Asetilkolinesteraz inhibitörü olarak tiyazolil-hidrazon türevleri üzerine çalışma

Yıl 2014, Cilt: 4 Sayı: 1, 38 - 42, 25.04.2014

Öz

Amaç: Bu çalışmada, tiyazolün bazı hidrazon türevlerinin sentezlerinin ve antikolinesteraz aktivitelerinin araştırılması amaçlandı. 

Yöntem: Pirol-2-karboksaldehidler tiyosemikarbazit ile etanol içinde direkt olarak reaksiyona tabi tutuldu ve oluşan tiyosemikarbazon, ?-bromoasetofenon türevleri ile (Hantzsch reaction) kondanse edilerek, 1-sübstitüe pirol-2-karboksaldehid (4-(4-sübstitüe fenil)-1,3-tiyazol-2-il)hidrazon türevlerini verdi. Bileşiklerin kimyasal yapıları, IR, 1H-NMR ve FAB+-MS spektral verileri ve elementel analiz verileri ile aydınlatıldı. Modifiye edilmiş Ellman spektrofotometrik metodu kullanılarak, elde edilen tüm bileşiklerin asetilkolinesteraz (AChE) inhibisyonları incelendi.

Bulgular: Bileşik 1, AChE üzerinde %64.10 (1 mM) and 33.00 (0.1 mM) inhibisyon oranları ve IC50=0.59 mM değeri ile en aktif antikolinesteraz molekül olarak belirlenmiştir.

Sonuçlar: Fenil halkası üzerinde para konumundan ve pirol halkasının 1. konumundan sübstitüsyonlar antikolinesteraz etkiyi negatif yönde etkilemiştir.

Anahtar Kelimeler : Tiyazol, hidrazon, pirol, antikolinesteraz aktivite

Kaynakça

  • Aderinwale GO, Ernst HW, Mousa SA. Current therapies and new strategies for the management of Alzheimer’s Disease. Am J Alzheimers Dis Other Demen. 2012;25: 414-424.
  • Dipiro J, Talbert RL, Yee GC, Matzke GR, Wells BG. Alzheimer’s disease. In: Jennifer Dea, eds. Pharmacotherapy: A Pathophysiology Approach. New York: NY McGraw-Hill; 2005.
  • Salloway S, Correia S. Alzheimer disease: time to improve its diagnosis and treatment. Cleve Clin J Med. 2009;76(1): 49-58.
  • Terry Jr. AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306: 821-827.
  • Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001; 81: 741-766.
  • Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res. 2004; 5: 433-440.
  • Asadipour A, Alipour M, Jafari M, Khoobi M, Emami S, Nadri H, Sakhteman A, Moradi A, Sheibani V, Moghadam FH, Shafiee A, Foroumadi A. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors. Eur J Med Chem. 2013; 70: 623-630.
  • Siddiqui N, Arshad MF, Ahsan W, Alam MS. Thiazoles: a valuable insight into the recent advances and biological activities. Int J Pharm Sci Drug Res. 2009; 1: 136-143.
  • Mustafa SM, Naira VA, Chittoorb JP, Krishnapillaic S. Synthesis of 1,2,4-triazoles and thiazoles from thiosemicarbazide and its derivatives. Mini-Rev Org Chem. 2004;1: 375-385.
  • Andreani A, Burnelli S, Granaiola M, Guardigli M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Rizzoli M, Varoli L, Roda A. Chemiluminescent high-throughput microassay applied to imidazo [2,1-b]thiazole derivatives as potential acetylcholinesterase and butyrylcholinesterase inhibitors. Eur J Med Chem. 2008;43: 657-661. Sengupta AK, Garg M. New 5-arylamino-2[N-(2’mercaptoacetylamino-4’-arylthiazolo)]thiadiazoles(III): as AChE inhibitors. J Indian Chem Soc. 1980;57: 1241-1243.
  • Shaw FH, Bentley GA. The pharmacology of some new anticholinesterases. Aust J Exp Biol Med Sci. 1953;31: 573–576.
  • Matsunaga Y, Tanaka T, Yoshinaga K, Ueki S, Hori Y, Eta R. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336: 791-800.
Toplam 12 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Articles
Yazarlar

Yusuf Özkay Bu kişi benim

Leyla Yurttaş Bu kişi benim

Usama Abu Mohsen Bu kişi benim

Belgin Sever Bu kişi benim

Weiam Hussein Bu kişi benim

Ömer Öztürk Bu kişi benim

Begüm Nurpelin Sağlık Bu kişi benim

Ulviye Acar Bu kişi benim

Özge Nurhan Erdoğan Bu kişi benim

Ayşen Pekbağ Bu kişi benim

Zafer Asım Kaplancıklı

Yayımlanma Tarihi 25 Nisan 2014
Gönderilme Tarihi 25 Nisan 2014
Yayımlandığı Sayı Yıl 2014 Cilt: 4 Sayı: 1

Kaynak Göster

APA Özkay, Y., Yurttaş, L., Abu Mohsen, U., Sever, B., vd. (2014). Asetilkolinesteraz inhibitörü olarak tiyazolil-hidrazon türevleri üzerine çalışma. Clinical and Experimental Health Sciences, 4(1), 38-42. https://doi.org/10.5455/musbed.20140101090010
AMA Özkay Y, Yurttaş L, Abu Mohsen U, Sever B, Hussein W, Öztürk Ö, Nurpelin Sağlık B, Acar U, Nurhan Erdoğan Ö, Pekbağ A, Kaplancıklı ZA. Asetilkolinesteraz inhibitörü olarak tiyazolil-hidrazon türevleri üzerine çalışma. Clinical and Experimental Health Sciences. Aralık 2014;4(1):38-42. doi:10.5455/musbed.20140101090010
Chicago Özkay, Yusuf, Leyla Yurttaş, Usama Abu Mohsen, Belgin Sever, Weiam Hussein, Ömer Öztürk, Begüm Nurpelin Sağlık, Ulviye Acar, Özge Nurhan Erdoğan, Ayşen Pekbağ, ve Zafer Asım Kaplancıklı. “Asetilkolinesteraz inhibitörü Olarak Tiyazolil-Hidrazon türevleri üzerine çalışma”. Clinical and Experimental Health Sciences 4, sy. 1 (Aralık 2014): 38-42. https://doi.org/10.5455/musbed.20140101090010.
EndNote Özkay Y, Yurttaş L, Abu Mohsen U, Sever B, Hussein W, Öztürk Ö, Nurpelin Sağlık B, Acar U, Nurhan Erdoğan Ö, Pekbağ A, Kaplancıklı ZA (01 Aralık 2014) Asetilkolinesteraz inhibitörü olarak tiyazolil-hidrazon türevleri üzerine çalışma. Clinical and Experimental Health Sciences 4 1 38–42.
IEEE Y. Özkay, “Asetilkolinesteraz inhibitörü olarak tiyazolil-hidrazon türevleri üzerine çalışma”, Clinical and Experimental Health Sciences, c. 4, sy. 1, ss. 38–42, 2014, doi: 10.5455/musbed.20140101090010.
ISNAD Özkay, Yusuf vd. “Asetilkolinesteraz inhibitörü Olarak Tiyazolil-Hidrazon türevleri üzerine çalışma”. Clinical and Experimental Health Sciences 4/1 (Aralık 2014), 38-42. https://doi.org/10.5455/musbed.20140101090010.
JAMA Özkay Y, Yurttaş L, Abu Mohsen U, Sever B, Hussein W, Öztürk Ö, Nurpelin Sağlık B, Acar U, Nurhan Erdoğan Ö, Pekbağ A, Kaplancıklı ZA. Asetilkolinesteraz inhibitörü olarak tiyazolil-hidrazon türevleri üzerine çalışma. Clinical and Experimental Health Sciences. 2014;4:38–42.
MLA Özkay, Yusuf vd. “Asetilkolinesteraz inhibitörü Olarak Tiyazolil-Hidrazon türevleri üzerine çalışma”. Clinical and Experimental Health Sciences, c. 4, sy. 1, 2014, ss. 38-42, doi:10.5455/musbed.20140101090010.
Vancouver Özkay Y, Yurttaş L, Abu Mohsen U, Sever B, Hussein W, Öztürk Ö, Nurpelin Sağlık B, Acar U, Nurhan Erdoğan Ö, Pekbağ A, Kaplancıklı ZA. Asetilkolinesteraz inhibitörü olarak tiyazolil-hidrazon türevleri üzerine çalışma. Clinical and Experimental Health Sciences. 2014;4(1):38-42.

14639   14640